AUSTRALIAN CLINICAL LABS LIMITED Financials Australian Clinical Labs Limited
Equities
ACL
AU0000148496
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.43 AUD | -0.82% |
|
+0.83% | -15.92% |
| Mar. 05 | Australia shares inch lower as miners weigh; GDP data in focus | RE |
| Feb. 28 | Australian Clinical Labs Falls 11% After Trimming Interim Dividend on Lower H1 FY24 EPS | MT |
Valuation
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 686.2 | 921.8 | 694.2 | 487.2 | - | - |
| Enterprise Value (EV) 1 | 750.3 | 895.4 | 740 | 526.5 | 505 | 486.6 |
| P/E ratio | 8.57 x | 5.19 x | 19.3 x | 17.1 x | 12.6 x | 11.3 x |
| Yield | 4.19% | 11.5% | 4.07% | 3.54% | 4.67% | 5.34% |
| Capitalization / Revenue | 1.02 x | 0.93 x | 1 x | 0.71 x | 0.68 x | 0.65 x |
| EV / Revenue | 1.11 x | 0.9 x | 1.06 x | 0.77 x | 0.71 x | 0.65 x |
| EV / EBITDA | 3.25 x | 2.4 x | 4.01 x | 2.84 x | 2.55 x | 2.33 x |
| EV / FCF | - | 3.41 x | 5.41 x | 14.8 x | 10.9 x | 10.1 x |
| FCF Yield | - | 29.4% | 18.5% | 6.77% | 9.17% | 9.93% |
| Price to Book | - | 3.99 x | - | 2.72 x | 2.45 x | 2.25 x |
| Nbr of stocks (in thousands) | 201,834 | 200,834 | 201,812 | 200,503 | - | - |
| Reference price 2 | 3.400 | 4.590 | 3.440 | 2.430 | 2.430 | 2.430 |
| Announcement Date | 8/25/21 | 8/9/22 | 8/21/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Junio | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 519.5 | 674.4 | 995.6 | 697.1 | 683.4 | 711.4 | 746.6 |
| EBITDA 1 | - | 230.7 | 372.7 | 184.7 | 185.6 | 198.3 | 208.4 |
| EBIT 1 | - | 140 | 266.6 | 61.99 | 60.95 | 70.99 | 77.56 |
| Operating Margin | - | 20.76% | 26.78% | 8.89% | 8.92% | 9.98% | 10.39% |
| Earnings before Tax (EBT) 1 | - | - | 254.9 | 48.31 | 41.55 | 54.71 | 62.11 |
| Net income 1 | 41.3 | 60.37 | 178.2 | 35.9 | 29.05 | 38.65 | 44.06 |
| Net margin | 7.95% | 8.95% | 17.9% | 5.15% | 4.25% | 5.43% | 5.9% |
| EPS 2 | - | 0.3969 | 0.8846 | 0.1785 | 0.1423 | 0.1931 | 0.2142 |
| Free Cash Flow 1 | - | - | 262.8 | 136.7 | 35.67 | 46.33 | 48.33 |
| FCF margin | - | - | 26.4% | 19.62% | 5.22% | 6.51% | 6.47% |
| FCF Conversion (EBITDA) | - | - | 70.52% | 74.02% | 19.21% | 23.37% | 23.19% |
| FCF Conversion (Net income) | - | - | 147.46% | 380.9% | 122.76% | 119.88% | 109.7% |
| Dividend per Share 2 | - | 0.1425 | 0.5300 | 0.1400 | 0.0860 | 0.1134 | 0.1297 |
| Announcement Date | 5/13/21 | 8/25/21 | 8/9/22 | 8/21/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 331.8 | 340.6 | 538 | 457.6 | 360.3 | 336.8 | 337.8 | 354.1 | 352.8 | 367.1 |
| EBITDA 1 | - | - | 239.3 | 133.4 | 99.82 | 84.93 | 87.1 | 100.8 | 97.8 | 102.6 |
| EBIT 1 | 68.6 | 71.4 | 191 | 75.6 | 38.96 | 23.03 | 15.94 | 37 | 32.6 | 38.2 |
| Operating Margin | 20.68% | 20.96% | 35.5% | 16.52% | 10.81% | 6.84% | 4.72% | 10.45% | 9.24% | 10.41% |
| Earnings before Tax (EBT) 1 | - | - | 184.9 | 69.96 | 32.76 | - | - | 28.75 | 24.4 | 30.2 |
| Net income 1 | - | - | 130.2 | 48.03 | 25.42 | 10.48 | 4.952 | 20.1 | 17 | 21.05 |
| Net margin | - | - | 24.2% | 10.5% | 7.06% | 3.11% | 1.47% | 5.68% | 4.82% | 5.73% |
| EPS 2 | - | - | 0.6454 | 0.2392 | 0.1265 | 0.0520 | 0.0246 | 0.1000 | 0.0850 | 0.1050 |
| Dividend per Share 2 | - | - | 0.1200 | 0.4100 | 0.0700 | 0.0700 | 0.0300 | 0.0440 | 0.0470 | 0.0575 |
| Announcement Date | 2/23/22 | 8/25/21 | 2/23/22 | 8/9/22 | 2/19/23 | 8/21/23 | 2/27/24 | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 64.1 | - | 45.7 | 39.3 | 17.8 | - |
| Net Cash position 1 | - | - | 26.4 | - | - | - | 0.64 |
| Leverage (Debt/EBITDA) | - | 0.2779 x | - | 0.2476 x | 0.2114 x | 0.0898 x | - |
| Free Cash Flow 1 | - | - | 263 | 137 | 35.7 | 46.3 | 48.3 |
| ROE (net income / shareholders' equity) | - | 118% | 113% | 18.7% | 17.5% | 21.1% | 21.5% |
| ROA (Net income/ Total Assets) | - | - | 32.1% | 6.54% | 4.7% | 6.45% | 7.05% |
| Assets 1 | - | - | 556.1 | 548.9 | 618.2 | 599.2 | 624.9 |
| Book Value Per Share 2 | - | - | 1.150 | - | 0.8900 | 0.9900 | 1.080 |
| Cash Flow per Share 2 | - | 1.010 | 1.410 | 0.7100 | 0.7700 | 0.8000 | 0.5600 |
| Capex 1 | - | - | 21.3 | 6.93 | 8.2 | 9.43 | 10.3 |
| Capex / Sales | - | - | 2.13% | 0.99% | 1.2% | 1.32% | 1.37% |
| Announcement Date | 5/13/21 | 8/25/21 | 8/9/22 | 8/21/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.43
AUD
Average target price
3.096
AUD
Spread / Average Target
+27.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.92% | 322M | |
| -14.08% | 85.02B | |
| +14.67% | 82.37B | |
| +9.37% | 29.29B | |
| -10.42% | 17.21B | |
| -0.36% | 16.7B | |
| +1.17% | 15.5B | |
| +4.32% | 12.15B | |
| -2.34% | 12.13B | |
| +32.51% | 12.12B |
- Stock Market
- Equities
- ACL Stock
- Financials Australian Clinical Labs Limited
